Allogene Therapeutics, Inc.

ALLO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001737287

Price chart

Open-market purchases and sales by ALLO insiders, newest first.

Insider trades
Filed (ET)Trade dateInsiderTransactionSharesAvg priceValueShares afterHolding changeFiling
Aug 25, 20264:43 PM ETAug 21, 2026Douglas Earl MartinSVP, General CounselSSaleCommon Stock−29.7K$2.12−$62.96K488.27K−5.7%SEC
Apr 23, 2026Apr 21, 2026Yoshiyama AnnieSVP, FinanceSSaleCommon Stock−9.59K$2.31−$22.14K124.52K−7.1%SEC
Apr 2, 2026Mar 31, 2026Beneski Benjamin MachinasSVP, Chief Technical OfficerSSaleCommon Stock−2.87K$2.50−$7.17K195.34K−1.4%SEC
Mar 18, 2026Mar 16, 2026Beneski Benjamin MachinasSVP, Chief Technical OfficerSSaleCommon Stock−4.84K$2.47−$11.94K198.21K−2.4%SEC
Mar 18, 2026Mar 16, 2026Chang David DPresident and CEOSSaleCommon Stock−47.76K$2.47−$117.97K5.15M−0.9%SEC

The largest institutional positions in ALLO at the end of Q2 2026.

Institutions holding ALLO in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
BlackRock, Inc.30,146,963$62.71M0.00%+11,055,868+57.9%Added
Pfizer Inc22,032,040$46.93M27.55%00.0%Unchanged
Frazier Life Sciences Management, L.P.22,446,668$46.69M1.02%+18,650,000+491.2%Added
STATE STREET CORP19,025,826$39.57M0.00%+10,365,520+119.7%Added
TPG GP A, LLC18,716,306$38.93M0.78%00.0%Unchanged